Growth hormone and insulin-like growth factors in haemopoiesis, lymphopoiesis and immune function

Endocrinology and Metabolism, Supplement

Volumn 3, Issue SUPPL. A, 1996, Pages 105-109

  Zegers, Ben J M ^a,b   Merchav, Shoshana ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GROWTH HORMONE; HEMOPOIETIC GROWTH FACTOR; PROLACTIN; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR;

CELLULAR IMMUNITY; CONFERENCE PAPER; ERYTHROPOIESIS; GROWTH HORMONE DEFICIENCY; HEMATOPOIESIS; HUMAN; HYPOPHYSECTOMY; IMMUNE RESPONSE; LYMPHOPOIESIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

EID: 0029494722     PISSN: 1074939X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Smith PE. Effect of hypophysectomy upon the involution of the thymus in the rat. Anat. Rec. 1930; 47: 119-129.
2. Basedowsky H, Sorkin E. Network of immune neuroendocrine interactions. Clin. Exp. Immunol. 1977; 27: 1-5.
3. Van Buul-Offers SC, Hoogerbrugge CM, Branger J, Feylbrief M, Van den Brande JL. Growth stimulating effects of somatomedin-insulin-like peptides in Snell dwarf mice. Horm. Res. 1988; 29: 229-336.
4. Murphy WJ, Durum SM, Anver MR, Longo DL. Immunologie and hématologie effects of neuroendocrine hormones. J. Immunol. 1992; 148: 3799-3805.
5. Salmon WD, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J. Lab. Clin. Med. 1957; 49: 825-836.
6. Kelly KW. Growth hormone, lymphocytes and macrophages. Biochem. Pharmacol. 1989; 38: 705-713.
7. Hooghe-Peters EL, Hooghe R. Growth hormone, prolactin and IGF-I as lymhpohemopoietic cytokines. N.Y. Austin: Springer-Verlag, 1995: 1-256.
8. Rechler MM, Nissley SP. The nature and regulation of the receptors for insulin-like growth factors. Annu. Rev. Physiol. 1985; 47: 425-442.
9. Metcalf D. Haemopoietic growth factors. Lancet 1989; i: 825-827.
10. Merchav S, Tatarsky l, Hochberg Z. Enhancement of erythropoiesis in vitro by human growth hormone is mediated by insulin-like growth factor I. Br. J. Haematol. 1988; 70: 267-271.
11. Hochberg Z, Hertz P, Maor G, Oikinine J, Aviram M. Growth hormone and insulin-like growth factor I increase macrophage uptake and degradation of lowdensity lipoprotein. Endocrinology 1992; 131: 430-435.
12. Muta K, Krantz S, Bondourant MC, Wickrema A. Distinct roles of erythropoietin, insulin-like growth factor I and stem cell factor in the development of erythroid progenitor cells. J. Clin. Invest. 1992; 94: 34-43.
13. Koury MJ, Bondourant MC. Erythropoietin retards DNA breakdown and prevents programmed cell death in erythroid progenitor cells. Science 1990; 248: 378-381.
14. Merchav S, Silvian-Drachsler I, Tatarsky I, Lake M, Skottner A. Comparative studies of the erythroidpotentiating effects of biosynthetic human insulin-like growth factors I and II. J. Clin. Endocrinol. Metab. 1992; 74: 447-452.
15. Murphy WJ, Tsarfaty G, Longo DL. Growth hormone exerts hematopoietic growth-promoting effects in vivo and partially counteracts the myelosuppressive effects of azidothymidine. Blood 1992; 80: 1443-1447.
16. Kurtz A, Zapf J, Eckard K, demons G, Froesch R, Bauer C. Insulin-like growth factor I stimulates erythropoiesis in hypophysectomized rats. Proc. Natl. Acad. Sci. USA 1988; 85: 7825-7829.
17. Philipps A, Persson B, Hall K, Lake M, Skottner A, Sanengen T, Sara W. The effects of biosynthetic insulin-like growth factor-l supplementation on somatic growth, maturation and erythropoiesis in the neonatal rat. Pediatr. Res. 1988; 23: 298-305.
18. Bechensteen AG, Halvorsen S, Skottner A. Recombinant human insulin-like growth factor I (rhIGF-l) stimulates erythropoiesis in adult, but not in newborn mice. Acta Physiol. Scand. 1994; 151: 117-123.
19. Tsarfaty G, Longo DL, Murphy WJ. Human insulin-like growth factor I exerts haemopoietic growth-promoting effects after in vivo administration. Exp. Hematol. 1994; 22: 1273-1277.
20. Merchav S, Tatarsky l, Hochberg Z. Enhancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor l/somatomedin C and human growth hormone. J. Clin. Invest. 1988; 81: 791-797.
21. Merchav S, Lake M, Skottner A. Comparative studies of the granulopoietic enhancing effects of biosynthetic human insulin-like growth factors I and II. J. Cell. Physiol. 1993; 157: 178-183.
22. Wiedermann CJ, Niedermuhlbichler M, Geissler D, Beimpold H, Bausteiner H. Priming of normal human neutrophils by recombinant growth hormone. Br. J. Haematol. 1991; 78: 19-22.
23. Fu YK, Arkins S, Wang BS, Kelley KW. A novel role of growth hormone and insulin-like growth factor I: priming neutrophils for Superoxide anion secretion. J. Immunol. 1991; 146: 1602-1608.
24. Hirai K, Miyamasu M, Yamaguchi M, Nakajima K, Ohtoshi T, Koshino T, Takaishi T, Morrita Y, Ito K. Modulation of human basophil histamine release by insulin-like growth factors. J. Immunol. 1993; 150: 1503-1508.
25. Edwards CK, Ghiasuddin SM, Yunger LM, Lorence RM, Arkins S, Dantzer R, Kelley KW. In vivo administration of recombinant growth hormone or gamma Interferon activates macrophages: enhanced resistance to experimental Salmonella typhimurium infection is correlated with generation of reactive oxygen intermediates. Infect. Immun. 1992; 60: 2514-2521.
26. Kelley KW, Arkins S. A role for IGF-I during myeloid cell growth and differentiation. In Insulin-like Growth Factors and their Regulatory Proteins. Baxter PC, Gluckman PD, Rosenfeld RG, editors. Amsterdam: Exerpta Medica, 1994: 315-327.
27. Holder A, Spencer EM, Preece MA. Effect of bovine growth hormone and a partially pure preparation of somatomedin on various growth parameters. J. Endocrinol. 1981; 89: 275-282.
28. Van Buul-Offers S, Ujeda I, Van den Brande JL. Biosynthetic somatomedin C increases the length and weight of Snell dwarf mice. Pediatr. Res. 1986; 20: 825-877.
29. Mathews LS, Hammer RE, Behringer RR, D'Ercole AJ, Bell Gl, Brinster RL, Palmiter RD. Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 1988; 123: 2827-2833.
30. Clark R, Strasser J, McCabe S, Robbius K, Jardieu P. Insulin-like growth factor-l stimulation of lymphopoiesis. J. Clin. Invest. 1993; 92: 540-548.
31. Kooijman R, Van Buul-Offers SC, Scholtens LE, Schuurman H-J, Van den Brande JL, Zegers BJM. T cell development in insulin-like growth factor-ll transgenic mice. J. Immunol. 1995; 154: 5736-5745.
32. Landreth KS, Narayanan R, Dorshkind K. Insulin-like growth factor-l regulates pro-B cell differentiation.
33. Landreth KS, Narayanan R, Dorshkind K. Insulin-like growth factor-l regulates pro-B cell differentiation. Blood 1992; 80: 1207-1212.
34. Gibson LF, Piktel D, Landreth KS. Insulin-like growth factor-l potentiates expansion of interleukin-7-dependent pro-B cells. Blood 1993; 82: 3005-3011.
35. Jardieu P, Clark R, Mortensen D, Dorshkind K. In vivo administration of insulin-like growth factor-l stimulates primary B lymphopoiesis and enhances lymphocyte recovery after bone marrow transplantation. J. Immunol. 1994; 152: 4320-4327.
36. Verland S, Gammeltoft S. Functional receptor for insulin-like growth factors I and II in rat thymocytes and mouse thymoma cells. Mol. Cell. Endocrinol. 1989; 67:207-271.
37. Kooijman R, Scholtens LE, Rijkers GT, Zegers BJM. Type I insulin-like growth factor receptor expression in different developmental stages of human thymocytes. J. Endocrinol. 1996; 147: 203-209.
38. Geenen V, Achour I, Robert E, Vandersmissen E, Sodoyez JC, Defresne MP, Boniver J, Lefebre PJ, Franchimont P. Evidence that insulin-like growth factor II is the dominant thymic peptide of the insulin superfamily. Thymus 1993; 21: 115-123.
39. Dardenne M, Savino W. Control of thymus physiology by peptidic hormones and neuropeptides. Immunol. Today 1994; 15:518-523.
40. Kooijman R, Willems M, de Haas CJC, Rijkers GT, Schuurman ALG, Van Buul-Offers SC, Heijnen CJ, Zegers BJM. Expression of type I insulin-like growth factor receptors on human peripheral blood mononuclear cells. Endocrinology 1992; 131: 2244-2254.
41. De Jong R, Brouwer M, Van Lier RA. Human CD8+ T lymphocytes can be divided into CD45RA+ and CD45RO+ cells with different requirements for activation and differentiation. J. Immunol. 1991; 146: 2088-2094.
42. Kooijman R, Scholtens LE, Rijkers GT, Zegers BJM. Differential expression of type I insulin-like growth factor receptors in different stages of human T cells. Eur. J. Immunol. 1995; 25: 931-935.
43. Kooijman R, Willems M, Rijkers GT, Brinkeman A, Van Buul-Offers SC, Heijnen CJ, Zegers BJM. Effects of insulin-like growth factors and growth hormone on the in vitro proliferation of T lymphocytes. J. Neuroimmunol. 1992; 38: 95-104.
44. Johnson EW, Jones LA, Kozak RW. Expression and function of insulin-like growth factor receptors on anti-CDS-activated human T lymphocytes. J. Immunol. 1992; 148:63-71.
45. Reiss K, Porcu P, Sell C, Pietrzkowskiz H, Baserga R. The insulin-like growth factor I receptor is required for the proliferation of hemopoietic cells. Oncogene 1992; 7: 2243-2248.
46. Ammann AJ, Sherman BM. Effect of growth hormone therapy on immune function. J. Pediatr. 1987; 110: 663-664.
47. Rongen-Westerlaken C, Rijkers GT, Scholtens EJ, Van Es A, Wit JM, Van den Brande JL, Zegers BJM. Immunologie studies in Turner syndrome before and during treatment with growth hormone. J. Pediatr. 1991; 119:268-272.
48. Wit JM, Kooijman R, Rijkers GT, Zegers BJM. Immunological findings in growth hormone treated patients. Horm. Res. 1993; 39: 107-110.
49. Saxena GB, Saxena RK, Adler WH. Regulation of natural killer activity in vivo III. Effect of hypophysectomy and growth hormone treatment on the natural killer activity of the mouse spleen cell population. Int. Arch. Allergy Immunol. 1982; 67: 169-174.
50. Bozzola M, Valtorta A, Moretta A, Cisternino M, Biscaldi l, Schimpft R. In vitro and in vivo effect of growth hormone on cytotoxic activity. J. Pediatr. 1990; 117:596-602.